What MRD test was used in EBLIS?

• A. Precise MRD
• B. Guardant360
• C. CAPP-Seq
• D. Signatera

Answer: (D)

MRD testing is most reliable when it tracks mutations known to come from the patient’s tumor. A tumor-informed approach does this by first sequencing the tumor to identify patient-specific mutations, then monitoring those exact mutations in blood over time. Signatera uses this strategy: it creates a personalized set of mutations from the tumor and then looks for those same mutations in circulating DNA with high sensitivity. This tailored, disease-specific tracking makes it particularly effective at detecting very small amounts of residual cancer and catching relapse earlier than imaging, which is why it’s used in EBLIS. Broad panels like Guardant360 profile many genes across patients but aren’t optimized for MRD and can miss low-level residual disease. CAPP-Seq is a sensitive MRD method, but Signatera’s clinically validated tumor-informed design provides the practical, standardized approach favored in this setting.